The brain level of perfluorododecanoic acid (PFDoA) was compared with those of perfluorooctanoic acid (PFOA) and perfluorodecanoic acid (PFDA) in rats 9 days after a single oral dose (50 mg/kg). The PFDoA level in the brain was 44.0 6 2.0 mg/g, which was higher than that in the serum (24.4 6 1.0 mg/ml). In contrast, the concentrations of PFOA and PFDA in the brain were low (<0.8 and 4.7 6 0.4 mg/g, respectively), and less than one-tenth of those in the serum. Next, to investigate the effects on brain function, the cognitive function alterations of PFOA, PFDA, and PFDoA were estimated by the novel object recognition test 5-6 days after dosing. A significant decrease in the discrimination index was observed in PFDoA-treated rats while no significant alteration was observed in PFDA-and PFOA-treated rats. The effects of PFDoA were further assessed by other behavioral tests. PFDoA-associated alteration was observed in the elevated-plus maze test, but not in the Y-maze test, open-field test, and forced swim test. A decrease in the discrimination index of the novel object recognition test was dependent on the PFDoA dose and the PFDoA concentration in the brain. PFDoA concentration in the brain was 28.6 6 2.6 mg/g 30 days after dosing, and a decrease in discrimination index was observed. Taken together, these results suggest that PFDoA distributes in the brain easier than PFOA and PFDA and causes cognitive deficit.
Perfluoroalkyl substances, including perfluoroalkyl acids (PFAAs) such as perfluorocarboxylic acids (PFCAs) and perfluoroalkyl sulfonic acids, have been manufactured and used for a variety of industrial applications and consumers products, such as surfactants in fire-fighting foam and cleaning agents, protective coatings for textiles, carpets, and electronic and photographic devices, since the 1950s (Buck et al., 2011; Renner, 2001) . In addition to direct emission through manufacturing process, PFAAs are emitted to the environment as terminal products of the degradation of precursor materials such as perfluoroalkyl sulfonamides, perfluoroalkyl telomer alcohols, and fluoropolymers (Prevedouros et al., 2006; Wang et al., 2013 Wang et al., , 2014 . PFAAs are widely spread and found in various environmental media, such as air, water, soil, sediment, and sludge from wastewater treatment plants (Kim and Kannan, 2007; Lau et al., 2007; Yamashita et al., 2005) , since PFAAs are highly stable and resistant to biodegradation (Key et al., 1997) . In 2001, Giesy and Kannan (2001) reported that PFAAs were present in wild life. To date, numerous studies have reported that PFAAs bioaccumulate in a wide variety of wild life, not only in industrialized countries but also in the Arctic and the Antarctic Oceans (Reiner and Place, 2015) . In addition, human biomonitoring studies have shown that the general populations in several countries have been exposed to PFAAs (Lau et al., 2007) and that perfluorooctanesulfonic acid (PFOS), perfluorooctanoic acid (PFOA), perfluorohexanesulfonic acid, and perfluorononanoic acid have routinely been detected, with PFOS levels being highest (Kato et al., 2011) .
Perfluorododecanoic acid (PFDoA), which has chain lengths of 12 carbons, has been reported to be found in human serum (Goralczyk et al., 2015) ; thus, humans are exposed to PFDoA (Gebbink et al., 2015) . The studies on the toxicity of PFCAs with carbon chain lengths longer than 10 are limited (Kato et al., 2015; Liu et al., 2016) ; therefore, it is necessary to estimate the toxicity of PFDoA. In general, PFCAs are thought to distribute predominantly to the blood, liver, and kidney, while having limited distribution to the brain in experimental animals (Kudo, 2015) . The levels of PFOS and PFOA in the brain are much less than in the serum in experimental animals, indicating that these chemicals hardly cross the blood-brain barrier (Mariussen, 2012) . The tissue distribution of PFOS and PFOA observed in wildlife exhibited similar tendencies. It is noteworthy that the brain concentrations of PFCAs with carbon chain lengths longer than 11 were close to those in the serum and liver of marine animals (Ahrens et al., 2009; Mariussen, 2012; Rubarth et al., 2011) , suggesting that these PFCAs can easily pass the blood-brain barrier compared with PFCAs with carbon chain lengths lesser than 10. We hypothesize PFDoA passes the blood-brain barrier and affects brain functions.
Various studies on the toxicities associated with exposure to PFAAs have shown hepatotoxicity (Kudo and Kawashima, 2003a, b) , developmental toxicity (Lau et al., 2004 (Lau et al., , 2007 , endocrine disrupting effects (Liu et al., 2015 (Liu et al., , 2016 , and immunotoxicity (DeWitt et al., 2012) in experimental animals. Compared with these toxic effects, less attention has been paid to the neurotoxic potentials. Chronic exposure to PFAAs was associated with small or no effect in adult animals (Butenhoff et al., 2009a (Butenhoff et al., , 2012 Fuentes et al., 2007c) . In contrast, neurobehavioral alterations were observed in developmentally exposed animals (Butenhoff et al., 2009b; Fuentes et al., 2007a, b; Johansson et al., 2008; Onishchenko et al., 2011; Ribes et al., 2010; Viberg et al., 2013) . The high sensitivity seems to be due to both weak bloodbrain barrier and vulnerability to the chemicals during the period of high neuronal growth (Eriksson, 1997) . It is possible that high concentrations of PFAAs lead to alterations in brain functions.
In this study, the neurobehavioral effects of PFCAs were estimated in relation to the concentrations of them in the brain of adult rats. We found that PFDoA distributed to the brain easier than PFOA and perfluorodecanoic acid (PFDA) and induced cognitive deficit in adult rats.
MATERIALS AND METHODS

Materials
PFDoA (>93%) was purchased from Tokyo Chemical Industry, Co. Ltd (Tokyo, Japan). PFOA (>98%) and PFDA (>96%) were from Sigma-Aldrich (St. Louis, MO., USA). 3-Bromoacetyl-7-methoxycoumarin was prepared as described (Ohya et al., 1998) . Corn oil was from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). All other chemicals were of analytical grade.
Animals and Treatments
All animal procedures were approved by the Institutional Animal Care Committee of Josai University in accordance with the Guidelines for Proper Conduct of Animal Experiments (Science Council of Japan). Male Wistar rats were purchased from SLC (Hamamatsu, Japan) and were allowed to acclimate to the housing facility for at least 1 week prior to treatment. Animals were given free access to water and food and were kept in a humidity-and temperature-controlled (23 6 2 C)
environment with a 12-h light/dark cycle.
Rats aged 8 weeks old were exposed to a single-oral dose of PFDoA at doses of 5, 20, and 50 mg/kg. A dose of 50 mg/kg was used for comparison of PFOA, PFDA, and PFDoA, since a significant alteration was observed with PFDoA at a dose of 50 mg/kg in the novel object recognition test without severe weight loss or less activity. All PFCAs were suspended in corn oil (4 ml/kg) and dosed to animals. All PFCAs were used without adjusting for the purity of the raw materials since exact purity was not given. These animals were subjected to behavioral tests as described below.
Behavioral Testing
Experimental protocols. Three sets of experiments were performed, and separate groups of rats were given each test. First set of experiments: the animals were divided into 6 groups (n ¼ 5-12), namely vehicle alone, PFDoA (5 mg/kg), PFDoA (20 mg/kg), PFDoA (50 mg/kg), PFOA (50 mg/kg), and PFDA (50 mg/kg) and received an oral gavage on Day 1. These animals were then tested in a novel object recognition test on Days 6 and 7. Some of the vehicle-or PFDoA-treated animals underwent the test on Days 29 and 30 (n ¼ 5).
Second set of experiments: the rats which had been treated with vehicle or PFDoA (50 mg/kg) on Day 1 underwent an openfield test on Day 6, followed by a Y-maze test on Day 8 (n ¼ 10).
Third set of experiments: the rats which had been treated with vehicle or PFDoA (50 mg/kg) on Day 1 underwent an elevatedplus maze test on Day 7, followed by a forced swim test on Days 8 and 9 (n ¼ 8).
Novel object recognition test. The novel object recognition test was performed to test for attention and memory in a lowmotivational state (Galeano et al., 2014) . The test was conducted in an opaque plastic enclosure (30 cm Â 25 cm Â 18 cm). The rat was habituated to the apparatus for 30 min 24 h before testing. Testing began with a 5-min information phase in the enclosure, where two identical objects (A/A 0 ) were placed for the animals to explore. After a resting period of 24 h in the home cage, the animal was then placed back in the enclosure, where one familiar object (A) and one novel object (B) were placed, and allowed to explore for 5 min (test phase). The test was recorded by a video camera, and the time that the snout pointed to each object was estimated as exploration time by two reviewers blinded to the conditions of the rats. Between sessions, the objects were cleaned with ethanol followed by water to avoid odor cues. The discrimination index was calculated using the following equation: Discrimination index ¼ (time spent on novel objectÀtime spent on familiar object)/time spent on both novel and familiar objects.
Y-maze test. The Y-maze test was performed to assess spatial working memory (Galeano et al., 2014) . The maze consisted of 3 equal, closed arms (12 cm Â 60 cm Â 20 cm) connected to the center at equal angles. The rat was placed on the center and allowed to move freely through the maze for 8 min. The test was recorded by a video camera, and the number of alternations and the number of arm entries were estimated by two reviewers blinded to the conditions of the rats. An arm entry was scored when rats placed 4 paws within the arm. An alternation was defined as an entry into 3 different arms on consecutive choice. The percent alternation was calculated as the ratio of actual to possible alternations using the following equation: Alternation (%) ¼ number of alternation/(number of arm entriesÀ 2) Â 100.
Elevated plus-maze test. The elevated plus-maze test was performed to assess anxiety versus risk-taking-like behavior (Galeano et al., 2014) . The maze consisted of 2 open arms (10 cm Â 50 cm) and 2 closed arms with a wall (10 cm Â 50 cm Â 40 cm) connected to a central platform (10 cm Â 10 cm) to form a cross. The maze was elevated to a height of 50 cm from the floor. A video camera was suspended above the maze. Forced swim test. The forced swim test was performed to assess behavioral despair (Porsolt et al., 1978) . The rat was placed in a glass cylindrical chamber (20 cm diameter Â 50 cm height) filled with water (30 cm height, 25 6 1 C). Two swimming sessions were carried out with an initial 15-min 'pre-test' followed by a 5-min 'test' after 24 h. Immobility time, defined as the period during which the animal floats in the water with only those movements necessary to keep its head above water, was evaluated by 2 reviewers blinded to the conditions of the rat.
Tissue Collection
Nine days after the oral gavage, the animals were anesthetized with diethyl ether, and blood was withdrawn from the inferior vena cava. Then, the whole body was perfused with $300 ml of ice-cold saline from the left ventricle to remove the blood. The brain and liver were quickly removed, weighed, frozen in liquid nitrogen, and stored at À80 C until use. Serum was prepared by centrifugation and stored at À30 C until analysis. Some rats were killed 30 days after dosing, and serum and tissue samples were obtained as described above. The liver and the brain were homogenized with 9 volumes of 0.25 M sucrose, 1 mM EDTA, and 10 mM Tris-HCl (pH7.4). A portion of the homogenate was subjected to PFCA analysis.
Analysis of PFCAs
The concentrations of PFCAs in the serum and tissue samples were determined as described previously (Ohya et al., 1998) . For determination of PFOA, PFDA, and PFDoA, a known amount of perfluorohexanoic acid, PFOA, and PFDA was added to the samples as internal standards, respectively, prior to extraction. In brief, PFCAs were extracted with ethyl acetate:hexane (1:1, v/v) from an aliquot of serum or tissue homogenates as an ion pair with tetrabutylammonium after adding an internal standard. The extract was then incubated with 3-bromoacetyl-7-methoxycoumarin to yield acetylmethoxycoumarin derivatives of PFCAs. The reaction mixture was separated with high performance liquid chromatography with a fluorescence detector. 
RESULTS
Body Weights, Organ Weights, and Tissue Concentration of PFCAs Body weights are shown in Table 1 on Day 10 for control, PFOA-, PFDA-, and PFDoA-treated rats (50 mg/kg body weight). Body weight in the PFDA group was significantly lesser than in the control, and those of the PFDoA group were slightly lesser than the control (Table 1) . Hepatomegaly was observed in all PFCA-treated groups (Table 1 ). The serum concentration of PFDoA was lesser than those of PFDA and PFDoA (Table 1 ). The hepatic concentration of PFDoA was comparative to that of PFDA and 4.2 times higher than PFOA (Table 1 ). The PFDoA concentration in the brain was greater than that of the serum, whereas the PFOA and PFDA concentrations were <5 mg/g brain ( Table 1) .
Effects of PFCA on Memory Function
To assess attention and memory in a low motivational state, the novel object recognition test was performed. In the information phase, no significant difference was observed in exploration time between two identical objects in all test groups on Day 6 ( Figure 1A ). In the test phase, rats in the vehicle, PFOA, and PFDA groups preferred the novel object over the familiar object, whereas PFDoA-treated rats did not ( Figure 1B) . The discrimination index was not altered in PFOA-treated rats, slightly, but not significantly, declined in PFDA-treated rats, and greatly declined in PFDoA-treated rats ( Figure 1D ). The total exploration time was not different between the 4 experimental groups ( Figure 1C ). The Y-maze test was also employed to assess spatial and working memory. No significant difference was observed in the percentage of alternation behavior and total arm entries between PFDoA-treated rats and vehicle-treated rats ( Table 2) .
Effects of PFDoA on Anxiety Behavior
The effects of PFDoA were estimated by the open-field test. No significant differences were observed in the mean distance traveled, the number of crossings, or the time spent in the central area between vehicle-and PFDoA-treated rats ( Table 2) .
The effects of PFDoA on anxiety were estimated by the elevated-plus maze test. The treatment with PFDoA significantly increased the time spent in the open arms (Figure 2A ), while the distance traveled, the total number of arm entries, and the percentage of open arm entry were not altered by the treatment with PFDoA (Figs. 2B-D) .
Effects of PFDoA on Depressive-like Behavior
In the forced-swim test, immobility time, which indicates a despair-like state, was not affected by the treatment with PFDoA (Table 2) .
Dose-Dependency and Duration of PFDoA-Induced Memory Deficit
The dose dependency of the PFDoA-induced decrease in the discrimination index was estimated in the novel object recognition test. A decrease in the discrimination index was observed at the doses over 20 mg/kg (Figure 3B ), while the total exploration time was unchanged at any dose ( Figure 3A) . The concentration of PFDoA increased in both the serum and brain as the dose of PFDoA increased ( Figure 3C) . The relationship between the concentration of PFDoA in the brain and the discrimination index revealed that a decrease in the discrimination index was observed when the PFDoA concentration was >20 mg/g tissue ( Figure 3D ). Memory deficit in the novel object recognition test was observed on Day 30 after an administration of PFDoA ( Figure 4B ), while the total exploration time was not altered ( Figure 4A ). The PFDoA concentrations in the serum and brain at 30 days after dosing were $70% of those at 9 days after dosing ( Figure 4C ). The body weight of PFDoA-treated rats was 355.8 6 8.3 g, which was slightly less than that of the control rats (379.8 6 8.3 g, P < .05).
DISCUSSION
In this study, we demonstrated that PFDoA is highly accumulated in the brain of adult rats that have received a single oral dose. This is different from PFOA and PFDA. PFDoA may distribute equally in the brain, since PFDoA concentrations of various parts in the brain were not different one another when rats were fed a diet admixed with 0.05% (w/w) PFDoA for 7 days (data not shown). To date, PFAAs were thought to accumulate primarily in protein-rich tissues, such as the liver and blood (Kudo, 2015) , with little distribution in the brain (Mariussen, 2012) . Several studies have revealed that the levels of PFAAs in the brain were lower than those in the liver and serum, indicating that most PFAAs have limited access to the brain. In adult rats, the levels of PFOS, PFOA, and perfluorononanoic acid were shown to be $1%-3% of those in the serum at low doses (Austin et al., 2003; Benskin et al., 2009; Kudo et al., 2007) . PFOS levels in the brain were >10% of those in the serum when rats were exposed to a sublethal dose of PFOS (Austin et al., 2003; Cui et al., 2009) . In the latter case, the high permeability of the brain to PFOS is thought to be due to membrane perturbation by high concentrations of PFOS in the serum . In studies of the tissue distribution of PFAA in wildlife, the brain levels of PFAA were lower than those in the serum (Mariussen, 2012) , except for PFDoA and perfluorotricosanoic acid of which the levels in the brain were equal and higher than those in the serum, respectively (Ahrens et al., 2009; Rubarth et al., 2011) . These observations on PFDoA are in accordance with the present results. The mechanism underlying the high distribution of PFDoA to the brain remains to be solved. Although the logK ow of PFDoA is not available experimentally, it was predicted to be 6.30, 8.23, and 10.16 for PFOA, PFDA, and PFDoA, respectively, by EPI suite software (Bhhatarai and Gramatica, 2011) . The high lipophilicity may be responsible for the high distribution of PFDoA to the brain.
The neurotoxic effects of PFAAs, especially PFOS and PFOA, were estimated in several studies and summarized by Mariussen (2012) . Most studies have shown developmental neurotoxicity, such as delays in neuromotor development, when animals were exposed to the chemicals prenatally or during the neonatal period (Mariussen, 2012) . A weak blood-brain barrier is thought to be responsible for the high sensitivity of developing animals. In contrast, studies on neurotoxicity in adult animals are limited. Butenhoff et al. (2009a) reported that repeated doses of perfluorohexanesulfonic acid exhibited no effects on the functional observational battery or on motor activity. Butenhoff et al. (2012) have shown that perfluorobutyric acid (PFBA) exhibited no effect on hearing, static righting, grip strength, or motor activity in adult rats that received oral gavages at doses of 30 and 150 mg/kg/day for 28 or 90 days. A delayed direct bilateral pupillary reflex was observed in male rats that chronically received PFOA at a dose of 30 mg/kg/day and PFBA at a dose of 150 mg/kg (Butenhoff et al., 2012) . In the study by Fuentes et al. (2007c) , oral exposure to PFOS for 4 weeks exhibited no effect in a functional observation battery, and small effects were observed at doses of 3 or 6 mg/kg/day in the open field test and Morris water maze test, although dose-dependency was not observed. The levels of PFAAs in brain might be low although the levels were not available in these studies. In contrast, this study demonstrated that treatment with PFDoA was associated with a significant cognitive deficit in adult rats, and that the effect continued for at least 4 weeks after dosing. It seems likely that the magnitude of the cognitive deficit is dependent on the concentration of PFDoA in the brain for the following reasons: (i) an inverse relationship was observed between the concentration of PFDoA in the brain and the discrimination index ( Figure 3D ); (ii) the decrease in the discrimination index was observed 30 days after dosing, when the concentration of PFDoA in the brain remained high ( Figure 4) ; (iii) PFOA, the level of which was <0.8 mg/g, did not alter the recognition index, and PFDA slightly, but not significantly, decreased the recognition index and was found in the brain (4.7 mg/g, Table 1 ).
To assess the neurotoxic effects of PFDoA, 5 behavioral tests were employed in this study: the novel object recognition test and Y-maze test to assess cognitive function, the open-field test and elevated-plus maze test to assess anxiety, and the forced swim test to assess depression. Treatment of PFDoA was associated with a significant deficit in novel object recognition tests (Figure 1) , while no significant difference was observed between the control and PFDoA-treated rats in Y-maze tests (Table 2 ). It seems likely that the novel object recognition test is more sensitive to neurotoxic substances compared with the Y-maze test (Ogundele et al., 2014; Tian et al., 2010) . PFDoA may not be strong enough to cause effects in the Y-maze test. Our results also suggested that PFDoA slightly decreased anxiety in the elevated plusmaze test (Figure 2) , while no significant effect was observed in the open-field test (Figure 2) . Although both the open-field test and the elevated-plus maze test assess anxiety-like behavior, these tests operationalize different aspect of emotional behavior (Ramos, 1998) . Alteration with PFDoA treatment may reflect a specific dimension of emotional behavior linked to the elevated-plus maze test. In contrast, PFDoA did not induce depression-like behavior ( Table 2) .
The mechanisms underlying the cognitive deficit associated with PFDoA treatment remains to be solved. Several in vitro studies have proposed mechanisms underlying neurobehavioral alterations associated with PFAAs. It has been shown that PFOS has a modulating effect on ion currents in cerebellar Purkinje cells (Harada et al., 2006) and in primary cultured hippocampal neurons . PFOS has been shown to alter Ca 2þ currents and increase the amplitude of field excitatory postsynaptic potentials in the CA1 region of hippocampal slices (Liao et al., 2008) . Liu et al. (2011) demonstrated that PFOS induced a disturbance of Ca 2þ homeostasis in hippocampal neurons. Ca 2þ is involved in the synaptic processes underlying both learning and memory, and the perturbation of Ca 2þ homeostasis interferes with physiological processes in neurons, including synaptic activity (Baker et al., 2013; Berridge, 1998) . PFDoA, like other PFAAs, may disturb Ca 2þ homeostasis in the brain.
In conclusion, this study demonstrated that PFDoA passes through the blood-brain barrier and accumulates in the brain. Cognitive deficit is associated with PFDoA levels in the brain.
